Thursday, January 20, 2005
Dr. John Dillon
Paul Lucas, President and CEO of GlaxoSmithKline Inc., is pleased to announce the appointment of Dr. John Dillon as Vice President, Research & Development and Chief Medical Officer.
Dr. Dillon will lead GSK’s team of R&D professionals committed to promoting excellence in Canadian health science research. He offers new perspectives for the Canadian R&D organization due to his considerable experience in the European pharmaceutical industry, and as a physician with Britain’s National Health Service.
After working in a number of hospitals, in family practice, and in industry in the United Kingdom, Dr. Dillon joined the company in 1996 and has held positions of increasing responsibility in the Medical Advisory, Clinical Research and Medical Affairs areas since that time.
Prior to his most recent appointment, Dr. Dillon was Vice President, Clinical, Europe in the Cardiovascular & Metabolic Medicines Development Centre of GSK.
Dr. Dillon was born and educated in Northern Ireland and graduated from University College, Dublin.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and health-care companies. In Canada, GlaxoSmithKline is among the top 20 contributors to research and development, across all industries, and is recognized as one of the country’s 50 best employers.
Back to top